Global Botulinum Toxin Market Size 2021 | To Hit USD 7.71 Billion at 7.5% CAGR by 2027; Increasing Awareness about the Therapeutic Benefits of Botox…

Pune, India, April 12, 2021 (GLOBE NEWSWIRE) -- Global Botulinum Toxins Market 2021 size will witness considerable growth in the coming years due to the inflating demand for botulinum toxinns across the world. The global botulinum toxin market size is projected to reach USD 7.71 billion by 2027, exhibiting a CAGR of 7.5% during the forecast period. Proven effectiveness of botox in treating chronic pain disorders will be a major factor propelling the growth of this market, states Fortune Business Insights in its report.

Escalating Demand for Botulinum Toxin Procedures to Create Attractive Growth Opportunities

The rising demand for improved aesthetic appearance has created a subsequent demand for botulinum toxin industry procedures around the world. Fortune Business Insights has identified increasing demand as one of the primary factors that are contributing to the growth of the global market. As far as therapeutics are concerned, the botulinum toxin holds massive potential with more than 100 approved botulinum toxin associated therapeutics existing in the market. Besides currently approved methods, there a host of therapeutic procedures that have lined up for clinical trials. The aforementioned factors will favor growth of the global botulinum toxins market in the forthcoming years.

Leading Players operating in the Botulinum Toxin Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/sample/botulinum-toxin-market-100996

Botulinum toxins are widely used for improving aesthetic appearances. The effectiveness of botulinum toxins in aesthetic applications such as treatment of moderate to severe glabellar lines have significantly contributed to the global botulinum toxin market growth. Anticipated regulatory approvals in therapeutic applications have led to significant botulinum toxins market growth. The increasing research and development initiatives aimed at the betterment of existing treatment methods, in addition to new methods, will favor growth of the market in the coming years. The high effectiveness of botulinum toxins in therapeutic applications have significantly contributed to the botulinum toxin market growth.

The growing awareness regarding side effects of botulinum toxins in developed as well as developing nations have will create several growth opportunities. Botulinum toxin is widely used for treating facial wrinkles and improving facial structures. The adoption of botulinum toxin industry is high in the United States, and this will favor the growth of the botulinum toxins market in North America.

Click here to get the short-term and long-term impacts of COVID-19 on this Market.

Please visit: https://www.fortunebusinessinsights.com/industry-reports/botulinum-toxin-market-100996

Out research methodology is robust and includes data triangulation based on bottom-up and top-down approaches. We validated the approximate market number with the help of primary research. Secondary research was conducted to find out detailed information about mergers & acquisitions, collaborations, joint ventures, and agreements. At the same time, we have derived significant information about the market dynamics associated with growth drivers, trends, and obstacles.

Increasing Product Launches Will Account for Substantial Growth

The high demand for botulinum toxin has led to several product innovations. Resulting from the high demand, there has been a subsequent rise in the number of product launches worldwide. Fortune Business Insights predicts that increasing product launches will constitute an increase in the overall botulinum toxins market value. With several market operators currently operating in the botulinum toxins industry, the market is set to surpass US$ 8000 Mn global value by 2026.

In January 2019, Huons Global announced the launch of a new botulinum toxin product in Korea. The Liztox was designed specifically to treat forehead wrinkles. The companys plans to extend its sales internationally will favor the global botulinum toxin market in the coming years. Additionally, the company completed several clinical trials for the product and gained approval from the Ministry of Food and Drug Safety in the same year. The report encompasses product launches, similar to Huons latest botulinum toxin product and signifies the importance of these products on the global botulinum toxin industry.

Quick Buy - Botulinum Toxin Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100996

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic. We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/botulinum-toxin-market-100996

Global Botulinum Toxin Market Segmentation

By Application

By End User

By Type

The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing. The financial parameters which are assessed include the sales, profits and the overall revenue generated by the key players of Market. Furthermore, the report offers a detailed analysis and information as per Pharmaceuticals Market Growth Analysis by manufacturers, market segments helping our readers to get a comprehensive overview of the global market. Several players are planning to focus on developing cost-effective products or services, aiming to maintain a strong foothold in the market.

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/botulinum-toxin-market-100996

Have a Look at Related Reports:

Gene Therapy Market Size, Share & COVID-19 Impact Analysis, By Application (Oncology, Neurology, and Others), By Vector Type (Viral and Non-viral), By Distribution Channel (Hospitals, Clinics, and Others), and Regional Forecast, 2020-2027

Diabetes Treatment Devices Market Size, Share & Industry Analysis, By Product (Insulin Pens, Insulin Pumps, Insulin Jet Injectors, Insulin Syringes, Others), By Distribution Channel (Institutional Sales, Retail Sales) and Regional Forecast, 2019-2026

Hyaluronic Acid Based Dermal Fillers Market Size, Share and Industry Analysis By Crosslinking Type (Monophasic, Biphasic), By Application (Scar Treatment, Wrinkle Correction Treatment, Lip Enhancement, Restoration of Volume/ Fullness), By End User(Specialty & Dermatology Clinics, Hospitals & Clinics) and Regional Forecast, 2019 2026

Vitamin D Testing Market Size, Share and Industry Analysis By Product (25 -Hydroxy Vitamin D Testing, 1,25-Dihydroxy Vitamin D Testing, 24,25-Dihydroxy Vitamin D Testing), By Application (Clinical Testing, Research Testing), By End User (Diagnostic Laboratories, Hospitals & Clinics, Others), and Regional Forecast 2019-2026

Veterinary Imaging Market Size, Share & COVID-19 Impact Analysis, By Product Type (X-ray, Ultrasound, Computed Tomography Systems, Magnetic Resonance Imaging Systems, and Others); By Application (Neurology, Oncology, Cardiology, Gynecology, Orthopedics, and Others); By Animal Type (Livestock Animals and Companion Animals), by End User (Veterinary Hospitals, Diagnostic Imaging Centers, and Others), and Regional Forecast 2020-2027

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone: US :+1 424 253 0390 UK : +44 2071 939123 APAC : +91 744 740 1245 Email: sales@fortunebusinessinsights.com Fortune Business Insights LinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/botulinum-toxin-market-9190

See the original post here:
Global Botulinum Toxin Market Size 2021 | To Hit USD 7.71 Billion at 7.5% CAGR by 2027; Increasing Awareness about the Therapeutic Benefits of Botox...

Adrenoleukodystrophy Treatment Market to Rise with Impressive CAGR | Players Viking Therapeutics, Nutra Pharma Corporation, Genetix Biotech Asia Pvt….

Decisive Markets Insights publishes detailed report on Global Adrenoleukodystrophy Treatment Market. Experts predict the market to grow exponentially from its earlier record of US$XX billion in 2019 to an estimated value of US$XX billion by 2027 with an annual compound growth rate of 6.1% over the next seven years. Nevertheless, the global COVID-19 pandemic, business has registered steady growth and there are huge prospects of investment opportunities.

In order to make a pre-order inquiry, kindly click on the link below:- https://decisivemarketsinsights.com/adrenoleukodystrophy-treatment-market/88689638/pre-order-enquiry

To avail Sample Copy of report, visit @ https://decisivemarketsinsights.com/adrenoleukodystrophy-treatment-market/88689638/request-sample

Key Companies Operating in this Market

bluebird bio, Inc., Orpheris, Inc., MedDay Pharmaceuticals, MINORYX THERAPEUTICS SL, Pfizer Inc., Amgen Inc., AstraZeneca, Abbott, agtc, ReceptoPharm, Inc., The Myelin Project, SOM Biotech SL, Viking Therapeutics, Nutra Pharma Corporation, Genetix Biotech Asia Pvt. Ltd., Magenta Therapeutics, NeuroVia, Inc., Novartis AG, CELGENE CORPORATION, Jazz Pharmaceuticals, Inc., Sanofi

Key Highlights of the Adrenoleukodystrophy Treatment Market Report

Market Segments and other perspective have been studied across 3600 perspective Both Supply and Demand side mapping has been done to understand the market scenario We have used data triangulation to derive the market numbers Our data and analysis have been verified through C-level Executives while conducting primary interviews Porters Five Forces Analysis, Swot, Analysis, PEST Analysis, Value Chain Analysis and Market Attractiveness would be an added advantage in the report Market Size is Provided from 2019 to 2027; whereas CAGR is Provided from 2020 to 2027 Historical Year: 2019; Base Year: 2020; Forecast Years: 2020 2027

Market Segmentation and Scope of the Global Adrenoleukodystrophy Treatment Market

Market by Type Medication, Gene Therapy, Bone Marrow Transplantation and Others

Market by Application Hospitals, Homecare, Specialty Clinics, Others

Kindly click on the link below if you intend to make a direct purchase.@ https://decisivemarketsinsights.com/adrenoleukodystrophy-treatment-market/88689638/buy-now

North America US, Mexico, Canada Europe Russia, Ukraine, France, Spain, Sweden, Norway, Germany, Finland, Poland, Italy, United Kingdom, Greece, Austria, Denmark, Switzerland, Netherlands, Belgium, Turkey, Luxembourg Asia-Pacific China, Japan, India, Australia, South Korea, Taiwan, Malaysia, Philippines, Thailand, Singapore South America- Brazil, Argentina, Peru, Chile Middle East and Africa Bahrain, Egypt, Israel, Kuwait, Qatar, Saudi Arabia, United Arab Emirates, South Africa

In the study, market trends and outlook are covered. Winning strategies and advice have been provided to help the reader take a strategic decision. Products through region and applications are mapped to understand the business scenario In the study, the competitive landscape covering the market share of key players is also listed. Extensive coverage of market drivers, restraints and opportunities, as well as impact analysis have also been provided

To inquire about the discount, kindly fill the form by clicking on the link below:-

https://decisivemarketsinsights.com/adrenoleukodystrophy-treatment-market/88689638/request-discount

Porters Five Analysis PEST Analysis Market Attractiveness Analysis Value Chain Analysis SWOT Analysis

Kindly contact us and our expert will get back to you within 30 minutes: Decisive Markets Insights Sunil Kumar Sales Head Email sales@decisivemarketsinsights.com US +18317045538 UK +441256636046

Follow this link:
Adrenoleukodystrophy Treatment Market to Rise with Impressive CAGR | Players Viking Therapeutics, Nutra Pharma Corporation, Genetix Biotech Asia Pvt....

Top Executives from AveXis Join New Gene Therapy Venture — This Time Targeting Tens of Millions More Patients – PRNewswire

MADISON, Wis., March 29, 2021 /PRNewswire/ --A pair of top C-level Executives from blockbuster gene therapy company AveXis have joined ENDSULIN, a new venture that could reach millions more than any gene therapy to date. Spearheaded by one of the disease's most accomplished pioneers, the company aims to upend a multi-billion dollar treatment industry.

Both Brian Kaspar and Thomas Dee, the founding Chief Science and Chief Finance Officers, respectively, of AveXis (developer of Zolgensma, bought by Novartis for $8.7 Billionin May of 2018) have accepted board roles at ENDSULIN. While AveXis sought to "transform rare diseases," ENDSULIN is solely targeting one of the most prolific Type 1 diabetes (T1D) with what they hope will be a one-time treatment to free patients from daily insulin injections by more precisely regulating their glycemic control.

"The science itself is remarkable, but the potential to change millions of lives is unprecedented," Kaspar said. "We've proven gene therapy can revolutionize medicine with lasting, durable treatments. But now we need players like ENDSULIN with the right vision and focus who can harness that momentum to give patients the relief they deserve."

The former AveXis leaders round out a team of pioneering experts at the forefront of diabetes, gene therapy and drug development, strategically brought together to accelerate ENDSULIN's undivided focus: FDA authorization to begin human clinical trials.

Founder Hans Sollinger's previous discoveries have shaped modern pancreatic transplantation treatment for T1D. But because of the complexity of the disease, while the science of management has advanced, insulin shots have been the enduring standard of care since the 1920s almost a full century.

"25 years ago, I had performed more kidney-pancreas transplants than anyone in the world, but I'd only helped 500 people," Sollinger said. "The most important aspect of my search for a cure became its reach, in terms of both scale and accessibility. As I advanced, it became more and more obvious that gene therapy was the way to achieve it all, with no compromises."

Through decades of research at the UW Hospitals and Clinics, Sollinger's team developed a highly unique and targeted expression system that addresses one of the greatest challenges in treating T1D: precise regulation of insulin in response to rapidly fluctuating glucose levels. Several publications over the last 10 years have demonstratedlong-lasting euglycemia control in hundreds of mice and rats, indicating a durable cure may be within reach.

"We've focused everything we are doing around our mission to get this treatment to patients," said Eric Spyra, Interim CEO and Board Member. "Using existing commercial infrastructure and following the path of other liver-directed AAV gene therapies, we're putting all the pieces in place now that will accelerate this therapy through every stage."

ENDSULIN has already initiated a pilot study in autoimmune-modeled naturally diabetic companion dogs, while executing their IND-enabling plan and preclinical studies. The company is preparing for a Series A funding round this year.

ABOUT ENDSULIN ENDSULIN is reshaping the way we approach a cure for diabetes. They are working to free patients from daily injections and 24/7 management using the most cutting-edge gene therapy technology, developed from decades of research by noted diabetes leader Hans Sollinger, MD, PhD, Dr hc, at the University of Wisconsin Hospitals and Clinics. Their sole focus is to get a durable, one-time treatment to the millions of people who need it.

SOURCE ENDSULIN

http://www.endsulin.com

See more here:
Top Executives from AveXis Join New Gene Therapy Venture -- This Time Targeting Tens of Millions More Patients - PRNewswire

Gene Therapy for CNS Disorders Market 2021 Industry Size, Share, Growth and Top Companies Analysis- Gilead (Kite Pharma), Amgen (BioVex), Novartis,…

DataIntelo recently publishes an all-inclusive report on the Global Gene Therapy for CNS Disorders Market providing a complete overview of the key aspects of the market. Gene Therapy for CNS Disorders market report makes a robust assessment regarding the current market situation and its scope, which are anticipated to impact significantly on the performance of the market during the forecast period, 2020-2027. This report includes an in-depth analysis about the COVID-19 situation and its possible impact on the market in the next few years. The report contains XX pages, which provides a precise and detailed explanation of key components and their market expansion scope in the mentioned period. The key insights about the potential size, volume, and dynamics of the market as mentioned in the report is a vital guideline that would help clients to make informed decision about their business investment plans and strategies in the market.

As per the analysis, the global Gene Therapy for CNS Disorders market was valued at USD XX million in 2019 and is projected to reach a value of USD XX million by the end of 2027, expanding at a CAGR of XX% during the forecast period.

Few of the key players mentioned in this report:

Gilead (Kite Pharma) Amgen (BioVex) Novartis Roche (Spark Therapeutics) Bluebird Bio

Get FREE Exclusive PDF Sample Copy of This Report: https://dataintelo.com/request-sample/?reportId=113131

The report covers a detailed study on key areas such as market size, scope, and growth opportunities of the global Gene Therapy for CNS Disorders market by analyzing the market trend and data available for the period prior to 2019. From this analysis, the report draws several observations and deduces about the key factors that drive or restrain the market growth, which would have a wide impact on the development and expansion of the market during the forecast period. Moreover, it covers a range of opportunities and challenges prevailing in the market that will help clients to evaluate their investment strategies.

The global Gene Therapy for CNS Disorders market report examine the major segments and sub-segmentations of the market that are classified as the product types, applications, and regions. In additional to the harsh economic impact of the COVID-19 outbreak, the report studies the dynamics of the market by analysis the key performance of each segments and the potential expansion scope of the segments in the coming years. Furthermore, the scope of the growth potential, revenue growth, product range, and pricing factors related to the global Gene Therapy for CNS Disorders market in terms of applications are thoroughly assessed in the report in a view to entail a broader picture of the market.

The report, published by DataIntelo, is the most reliable information as the study consists of a concise graphical representations, tables, and figures which allow the users to easily understand the key market position of sectors or segment without going through a deep study of the report. The tables and figures represent the latest update information that provides a broad picture of several market developments of the products and services over the last few years.

Customize Report and Inquiry for the Gene Therapy for CNS Disorders market report @ https://dataintelo.com/enquiry-before-buying/?reportId=113131

The market report relies on a concrete research methodology focusing on both primary as well as secondary sources. The report is prepared by relying on primary source including interviews of the company executives & representatives and accessing official documents, websites, and press release of the private and public companies. Additionally, this report includes market analysis from several global experts and analysts who have in-depth knowledge about the market. To ensure a complete framework of the market, it also adopts several research tools such as statistical surveying for SWOT analysis, PESTLE analysis, predictive analysis, and real-time analytics.

Global Gene Therapy for CNS Disorders market by Products

Ex Vivo In Vivo

Global Gene Therapy for CNS Disorders market by Applications

Hospitals Clinics Others

You can buy the complete report in PDF format @ https://dataintelo.com/checkout/?reportId=113131

The report mentions some key global players in the market and additional names of the players in the market can be included as per the clients request. Moreover, a customized or separate report can also be available according to the needs of clients. The report covers the recent development of players including merger & acquisition agreements, partnership or joint venture and latest products launches from the key manufacturers in the Gene Therapy for CNS Disorders market. Please contact with our sales team, who will deliver reports that suits your necessities.

Competition Landscape

The report covers global aspect of the market, covering

North America Latin America Europe Asia Pacific Middle East and Africa

About DataIntelo:

DataIntelo is a globally leading distributor of market research report that has experienced by dealing with more than 800+ global clients. We offer quality market research report and provide data that can help generate a totally new approach for our clients to help change the outlook of their investment and business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

See the original post:
Gene Therapy for CNS Disorders Market 2021 Industry Size, Share, Growth and Top Companies Analysis- Gilead (Kite Pharma), Amgen (BioVex), Novartis,...

Gene Therapy for Hemophilia Market will Reach Thriving Value by 2019 to 2028 SoccerNurds – SoccerNurds

A new research study titled Global Gene Therapy for Hemophilia market successfully portrays the entire global scenario as well as a detailed analysis of various regional segments.

Request Sample [emailprotected]https://insights10.com/free-sample-report-inquiry/?id=9158

The Gene Therapy for Hemophilia market research includes an examination of the leading geographies, such as North America (U.S., Canada), Europe (Germany, France, U.K., Spain, Italy, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia, and Rest of Asia Pacific) Latin America ( Mexico, Brazil, Rest of Latin America) and Middle East & Africa (GCC countries, South Africa, and Rest of Middle East & Africa) for the period of 2019 to 2028.

The study on the Gene Therapy for Hemophilia market is a detailed review and presentation of the global industrys drivers, constraints, opportunities, demand factors, market size, historical data forecasts, and trends from 2019 to 2028. The study also assists in the comprehension of global Gene Therapy for Hemophilia market dynamics and structure by defining and evaluating market segments, as well as forecasting global market size.

Top Participants in the Gene Therapy for Hemophilia Market

F. Hoffmann-La Roche AG, Pfizer Inc., BioMarin Pharmaceuticals, uniQure and, Shire PLC.

Global Gene Therapy for Hemophilia Market Segmentation

A. By Class

I. Viral Vector II. Non-Viral Vector

B. Distribution Channel

I. Hospital Pharmacies II. Clinics III. Others

C. Geography

I. North America Market Analysis II. Europe Market Analysis III. Asia-Pacific Market Analysis IV. Middle-East and Africa Market Analysis

View Detail [emailprotected]https://insights10.com/product/global-gene-therapy-hemophilia-market/

Table Of Content of Global Gene Therapy for Hemophilia Market

1. Global Gene Therapy for Hemophilia Market Overview. A. Market Size 2. Market Growth Drivers.. A. Rise in Global Prevalence of Gene Therapy for Hemophilia B. Growing R&D Investments and Reimbursement Policies 3. Gene Therapy for Hemophilia Market Segmentation. A. By Class I. Viral Vector II. Non-Viral Vector B. Distribution Channel I. Hospital Pharmacies II. Clinics III. Others C. Geography I. North America Market Analysis II. Europe Market Analysis III. Asia-Pacific Market Analysis IV. Middle-East and Africa Market Analysis 4. Gene Therapy for Hemophilia Disease Major Market Share.. A. Market Analysis, Insights and Forecast By Revenue 5. Competitive Landscape. A. Major Players B. Products in Pipeline 6. Key Company Profiles A. Pfizer overview, Product & Services, Strategies & Financials B. Shire PLC Company overview, Product & Services, Strategies & Financials C. Roche Company, Product & Services, Strategies & Financials 7. Healthcare Policies and Regulatory Landscape. A. Policy changes and Reimbursement scenario 8. Factors Driving Future Growth.. A. New Trends and Development of Gene Therapy for Hemophilia market B. Future Opportunities 9. Barriers in Future Growth. 10. Conclusion

The report also looks at key players competitive environment in terms of product, value, financial situation, product portfolio, growth strategy, and regional presence. The study includes a value chain analysis and a SWOT analysis to address the issue of whether shareholders should concentrate their efforts and investments in the near future on the Gene Therapy for Hemophilia markets emerging segment. Furthermore, the report is a collective presentation of primary and secondary research findings.

Buy [emailprotected]https://insights10.com/checkout/

Contact:

Email :[emailprotected]

ContactNumber :+91 79 4009 3656

Continue reading here:
Gene Therapy for Hemophilia Market will Reach Thriving Value by 2019 to 2028 SoccerNurds - SoccerNurds

Hemophilia Treatment Market Analysis to 2025 – Growth Trends and Changes Influencing the Industry – Technology Magazine

Global hemophilia treatment market is inclined to accumulate substantial returns over the ensuing years owing to the rising cases of genetic abnormalities and increasing prevalence of hemophilia. Hemophilia is a rare bleeding disorder, which causes incessant or prolonged bleeding after an injury or surgery due to delayed blood clotting. Quality care and efficient treatment can help prevent some serious consequences of the disorder.

Development of advanced treatment technologies such as hemophilia gene therapy is slated to further augment market growth in the succeeding years. Biotechnology companies have been particularly proactive in this regard, working on investigational gene therapies for patients with severe hemophilia A. Successful execution and approval of hemophilia gene therapy will have a substantial effect on hemophilia treatment market size in the future.

Request for a sample copy of this report @ https://www.gminsights.com/request-sample/detail/2772

Based on product, the recombinant factor concentrates segment is poised to exhibit a growth rate of 5% through 2025, as a result of low disease transmission risks and its prevention of viral infection. Additionally, the product is capable of increasing the replacement therapy safety.

The global hemophilia treatment market from the adult segment recorded revenue worth $6,778.2 million in 2018, as adult patients have high chances of developing moderate to severe hemophilia. As per authentic reports, over 65% of the patients diagnosed with hemophilia are adults.

With regards to the treatment spectrum, the global hemophilia treatment market from the prophylaxis treatment segment registered remuneration of $7,219.9 million in 2018 and is set to account for a major market share over the forecast spell, which can be credited to its effectiveness in treating bleeding episodes and joint pain.

Based on end-use, the hemophilia treatment centers segment is poised to register a growth rate of 4.6% through 2025, which can be attributed to the enhanced care services provided by these centers as compared to clinics and hospitals.

Major industry players have executed several growth strategies such as collaborations, new launches, and mergers to reinforce their position in the global hemophilia treatment market. In 2017, patients with hemophilia A received a more long-lasting option with Roches Hemlibra. The drug received approval from Health Canada for hemophilia A patients deprived of factor VIII inhibitors as routine prophylaxis to prevent bleeding or reduce its frequency. Increasing demand for Roches Hemlibra and similar medications among hemophilia A patients would escalate hemophilia treatment industry share.

The competitive landscape of the hemophilia treatment market comprises of companies such as Genentech, Biotest AG, Swedeish Orphan Biovitrum AB, and Sanofi SA, among others. These firms are focusing on expanding their stance in the global market through various strategies including partnerships and innovative product launches.

Request for customization @ https://www.gminsights.com/roc/2772

Partial Chapter of the Table of Content

Chapter 5. Hemophilia Treatment Market, By Product

5.1. Global market share by product, 2018 & 2025

5.2. Recombinant Factor Concentrates

5.2.1. Market size, by region, 2014 2025 (USD Million)

5.2.2. Factor VIII

5.2.2.1. Market size, by region, 2014 2025 (USD Million)

5.2.3. Factor IX

5.2.3.1. Market size, by region, 2014 2025 (USD Million)

5.3. Plasma-derived Factor Concentrates

5.3.1. Market size, by region, 2014 2025 (USD Million)

5.3.2. Factor VIII

5.3.2.1. Market size, by region, 2014 2025 (USD Million)

5.3.3. Factor IX

5.3.3.1. Market size, by region, 2014 2025 (USD Million)

5.4. Extended Half-life Products

5.4.1. Market size, by region, 2014 2025 (USD Million)

5.4.2. Factor VIII

5.4.2.1. Market size, by region, 2014 2025 (USD Million)

5.4.3. Factor IX

5.4.3.1. Market size, by region, 2014 2025 (USD Million)

5.5. Others

5.5.1. Market size, by region, 2014 2025 (USD Million)

Browse full table of contents (TOC) of this report @ https://www.gminsights.com/toc/detail/hemophilia-treatment-market

Read this article:
Hemophilia Treatment Market Analysis to 2025 - Growth Trends and Changes Influencing the Industry - Technology Magazine

Alpha Thalassemia Market Global Production, Growth, Share, Demand and Applications Forecast to 2027 NeighborWebSJ – NeighborWebSJ

Alpha Thalassemia Market Forecast 2020-2027

The Global Alpha Thalassemia Market research report provides and in-depth analysis on industry- and economy-wide database for business management that could potentially offer development and profitability for players in this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It offers critical information pertaining to the current and future growth of the market. It focuses on technologies, volume, and materials in, and in-depth analysis of the market. The study has a section dedicated for profiling key companies in the market along with the market shares they hold.

The report consists of trends that are anticipated to impact the growth of the Alpha Thalassemia Market during the forecast period between 2020 and 2027. Evaluation of these trends is included in the report, along with their product innovations.

Get a PDF Copy of the Sample Report for free @ https://www.upmarketresearch.com/home/requested_sample/39552

The Report Covers the Following Companies: Bluebird Bio Novartis Kiadis Pharma Acceleron Pharma

By Types: Iron Chelating Drugs Gene Therapy

By Applications: Hospitals Private clinics Other

Furthermore, the report includes growth rate of the global market, consumption tables, facts, figures, and statistics of key segments.

By Regions:

Grab Your Report at an Impressive Discount! Please click here @ https://www.upmarketresearch.com/home/request_for_discount/39552

Years Considered to Estimate the Market Size: History Year: 2015-2020 Base Year: 2020 Estimated Year: 2020 Forecast Year: 2020-2027

Important Facts about Alpha Thalassemia Market Report:

What Our Report Offers:

Make an Inquiry of This Report @ https://www.upmarketresearch.com/home/enquiry_before_buying/39552

About UpMarketResearch: Up Market Research (https://www.upmarketresearch.com) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info UpMarketResearch Name Alex Mathews Email [emailprotected] Organization UpMarketResearch Address 500 East E Street, Ontario, CA 91764, United States.

https://neighborwebsj.com/

Here is the original post:
Alpha Thalassemia Market Global Production, Growth, Share, Demand and Applications Forecast to 2027 NeighborWebSJ - NeighborWebSJ

Global Retinitis Pigmentosa (Retinitis) Market demand with COVID-19 recovery analysis 2021 better delivery process to boost market growth by 2026 KSU…

Retinitis-Pigmentosa-(Retinitis)-MarketLatest research on Global Retinitis Pigmentosa (Retinitis) Market report covers forecast and analysis on a worldwide, regional and country level. The study provides historical information of 2016-2021 together with a forecast from 2021 to 2026 supported by both volume and revenue (USD million). The entire study covers the key drivers and restraints for the Retinitis Pigmentosa (Retinitis) market. this report included a special section on the Impact of COVID19. Also, Retinitis Pigmentosa (Retinitis) Market (By major Key Players, By Types, By Applications, and Leading Regions) Segments outlook, Business assessment, Competition scenario and Trends .The report also gives 360-degree overview of the competitive landscape of the industries.Moreover, it offers highly accurate estimations on the CAGR, market share, and market size of key regions and countries. Players can use this study to explore untapped Retinitis Pigmentosa (Retinitis) markets to extend their reach and create sales opportunities.

Some of the key manufacturers operating in this market include: Sanofi, Amgen, Amarantus Bioscience Holdings, Acucela, Applied Genetic Technologies Corp, Asklepios BioPharmaceutical, Astellas Pharma, Caladrius Biosciences, Dompe Farmaceutici SpA, Dormant Projects, GenSight Biologics SA, Grupo Ferrer Internacional SA, ID Pharma, InFlectis BioScience, Ionis Pharmaceuticals, Mimetogen Pharmaceuticals, Ms Science Corp, Nanovector srl, Novartis AG, Novelion Therapeutics, ProQR Therapeutics, ReNeuron Group Plc, SanBio, Shire (Takeda Pharmaceutical), Spark Therapeutics and More

Download Free PDF Sample Copy of the Report(with covid 19 Impact Analysis): https://www.globmarketreports.com/request-sample/61185

Our Research Analyst implemented a Free PDF Sample Report copy as per your Research Requirement, also including impact analysisofCOVID-19 on Retinitis Pigmentosa (Retinitis) Market Size

Retinitis Pigmentosa (Retinitis) market competitive landscape offers data information and details by companies. Its provides a complete analysis and precise statistics on revenue by the major players participants for the period 2021-2026. The report also illustrates minute details in the Retinitis Pigmentosa (Retinitis) market governing micro and macroeconomic factors that seem to have a dominant and long-term impact, directing the course of popular trends in the global Retinitis Pigmentosa (Retinitis) market.

Based on the type of product, the global Retinitis Pigmentosa (Retinitis) market segmented into: General Treatment Traditional Chinese Medicine Gene Therapy The Surgical Treatment Others

Based on the end-use, the global Retinitis Pigmentosa (Retinitis) market classified into: Hospitals Eye Clinics Others

Regions Covered in the Global Retinitis Pigmentosa (Retinitis) Market:

1. South America Retinitis Pigmentosa (Retinitis) Market Covers Colombia, Brazil, and Argentina. 2. North America Retinitis Pigmentosa (Retinitis) Market Covers Canada, United States, and Mexico. 3. Europe Retinitis Pigmentosa (Retinitis) Market Covers UK, France, Italy, Germany, and Russia. 4. The Middle East and Africa Retinitis Pigmentosa (Retinitis) Market Covers UAE, Saudi Arabia, Egypt, Nigeria, and South Africa. 5. Asia Pacific Retinitis Pigmentosa (Retinitis) Market Covers Korea, Japan, China, Southeast Asia, and India.

Years Considered to Estimate the Market Size: History Year: 2015-2021 Base Year: 2021 Estimated Year: 2021 Forecast Year: 2021-2026

Get Chance of up to 50% Extra Discount@: https://www.globmarketreports.com/request-discount/61185

Reasons to buy:

Some Major TOC Points:

For More Information with including full TOC: https://www.globmarketreports.com/industry-reports/61185/Retinitis-Pigmentosa-(Retinitis)-market

Key highlights of the Retinitis Pigmentosa (Retinitis) Market report: Growth rate Renumeration prediction Consumption graph Market concentration ratio Secondary industry competitors Competitive structure Major restraints Market drivers Regional bifurcation Competitive hierarchy Current market tendencies Market concentration analysis

Customization of the Report: Glob Market Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Get Customization of the Report@: https://www.globmarketreports.com/request-customization/61185

Contact Us: Glob Market Reports 17224 S. Figueroa Street, Gardena, California (CA) 90248,United States Call:+1 915 229 3004(U.S) +44 7452 242832(U.K) Website: http://www.globmarketreports.com

View original post here:
Global Retinitis Pigmentosa (Retinitis) Market demand with COVID-19 recovery analysis 2021 better delivery process to boost market growth by 2026 KSU...

ASCO Names Molecular Profiling in GI Cancers as Advance of the Year – OncLive

Molecular profiling has paved the way for several advances in the treatment of patients with gastrointestinal (GI) malignancies, by identifying critical markers and gene signatures that allow for the delivery of options that are personalized to each tumor. To this end, ASCO has chosen molecular profiling driving progress in GI cancers as its Advance of the Year.1

The organization made the announcement as part of its Clinical Cancer Advances 2021: ASCOs Annual Report on the Progress Against Cancer. The annual update shines a light on important clinical research milestones and policy developments that have been made over the past year; the report also spotlights areas of opportunity to address unmet needs with future efforts.

Molecular profiling tools such as next-generation sequencing give us the ability to identify specific molecular and genomic-targeted treatments that are likely to benefit an individual patient, Howard A. Skip Burris, III, MD, FACP, FASCO, ASCO board chairman, stated in a press release.2 Personalized medicine is becoming a reality.

Although treatments such as surgery, radiotherapy, and chemotherapy have served as the mainstay of treatment in patients with GI cancers, these approaches have limited efficacy and can negatively impact quality of life, according to the report. Although the development of more effective approaches has lagged, the advent of molecular profiling has helped to expand options for these patients; this has resulted in longer survival with minimal adverse effects.

The ability to identify genetic abnormalities, such as mutations, amplifications, or fusions, as well as epigenetic profile, protein expression, or other molecular features has allowed for patients to be matched with the appropriate targeted therapy for their specific tumor. In the past year, HER2-targeted agents have been shown to improve survival in patients with gastric cancer; this approach is showing similar potential in patients with HER2-positive colorectal cancer (CRC).

Several HER2-targeted agents are being examined in patients with GI cancers. For example, the safety and efficacy of the novel HER2-targeted antibodydrug conjugate (ADC) fam-trastuzumab deruxtecan-nxki (Enhertu) was evaluated in patients with HER2-positive gastric or gastroesophageal cancers who had progressed on trastuzumab (Herceptin) as part of the phase 2 DESTINY-Gastric01 trial (NCT03329690).3

Patients who received trastuzumab deruxtecan achieved an objective response rate (ORR) of 51.3% versus 14.3% in those who received chemotherapy. Patients on the trastuzumab deruxtecan arm also experienced an improvement in median overall survival (OS) compared with those on the chemotherapy arm, at 12.5 months versus 8.4 months, respectively (HR, 0.59; 95% CI, 0.39-0.88; P = .0097). The benefit achieved with the ADC led to the January 2021 approval of trastuzumab deruxtecan for use in adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who had previously received a trastuzumab-based regimen.4

Additional data on the agent were presented during the 2020 ASCO Virtual Scientific Program. In thephase 2 DESTINY-CRC01 study (NCT03384940), trastuzumab deruxtecan was examined in 78 patients with HER2-expressing, metastatic CRC who had progressed on 2 or more prior regimens. Here, 1 patient experienced a complete response to treatment, while 23 experienced partial responses.5 In this population, the agent yielded an ORR of 45.3%.

Another advancement was the June 2020 FDA approval of first-line pembrolizumab (Keytruda) for patients with microsatellite instabilityhigh or mismatch repair deficient CRC.6 This regulatory decision on was based on the results from the phase 3 KEYNOTE-177 trial (NCT02563002), in which the PD-1 inhibitor was found to double the time to disease progression versus standard chemotherapy, at 16.5 months versus 8.2 months, respectively.7 Moreover, pembrolizumab resulted in a significant 40% reduction in the risk of disease progression or death versus chemotherapy (HR, 0.60; 95% CI, 0.45-0.80; P = .0004).

The report also examined health inequities in cancer care and clinical research. Although overall cancer-related mortality has decreased in the United States, underserved patient populations still experience lower survival; these populations include black patients, those residing in rural areas, and those with lower incomes and education levels.8,9

Disparities in cancer research is a complex, multifaceted issue requiring a multifactorial response that addresses (1) specific interrelated barriers precluding certain populations from trial participation, and (2) structural and systemic challenges that limit the cancer communitys pursuit of research that would benefit underserved populations, the authors of the report write.

Some obstacles to equitable cancer research can include structural barriers, such as a lack of access to clinics offering clinical trials, as well as transportation and health insurance; clinical barriers, such as eligibility criteria; patient attitudes regarding trials, which could stem from historical inequities and a lack of informed consent; and physician attitudes, such as not offering underserved patients the opportunity to enroll to relevant clinical trials.

The authors of the report suggest several strategies to potentially improve equity in clinical cancer research. To this end, ASCO and Friends of Cancer Research have been working together to finalize 4 new Guidance for Industry documents that would broaden eligibility criteria for clinical trials by lowering the minimum participation age and to include patients with brain metastases who have been treated and are stable. Additionally, expanded guidelines would include patients with human immunodeficiency virus and hepatitis B and C virus, and recommend less restrictive renal, cardiac, and hepatic function criteria.

Other efforts include umbrella and basket trial designs, broadening trial availability, improving patient education and navigation, developing new consent strategies, and providing more financial assistance plans.

Among the numerous developments listed in the report, authors underscored the importance of artificial intelligence (AI) technology, a complex field of medical research that has grown exponentially in recent years. Authors of the report noted that AI technology can potentially be used to integrate a wealth of data points into a clinically meaningful context.

Currently, several types of AI are being utilized in the field of oncology, including deep learning methods that are able to identify relationships within data to solve complex problems through the utilization of algorithms in an iterative process. This technology could help to advance diagnostic, therapeutic, and translational research in both cancer prevention and treatment.

Key areas of interest include the development of deep learning methodologies to help with diagnosing cancer based on biospecimen analysis; using AI to improve radiographic imaging, analysis, and reporting; and using these systems to integrate vast amounts of clinical data to assist in the clinical decision-making process and measure outcomes.

It will be critical to educate oncologist about the fundamentals, advantages, and potential pitfalls of AI and deep learning techniques to support effective application in real-world cancer care, according to the authors of the report.

The coronavirus disease 2019 (COVID-19) pandemic has provided a unique opportunity for investigators to reconsider how clinical cancer research can be conducted and to examine disparities that exist with regard to clinical trial participation. Within the first weeks of the pandemic, 60% of US research institutions froze screening and enrollment for clinical trial research.10

To address this, investigators and institutions, with help from the FDA and the National Comprehensive Cancer Network, took action. To avoid the shutdown of clinical trials, investigator and sponsors found ways to allow for some flexibility, while preserving the integrity of the research. Remote patient monitoring and drug administration were permitted, and guidance was created to allow for virtual consent using e-signatures and limited collection of research-only biospecimens. Moreover, patients were allowed to have their local healthcare providers perform blood draws and imaging scans for these efforts.

Although the pandemic spotlighted existing racial and socioeconomic disparities, it also underscored the ability of the oncology community to rapidly respond to significant, unexpected disruptions to care and research efforts.

This same ingenuity and flexibility can and should be applied to improving health equity for all individuals, so that right treatment truly is delivered to the right patient at the right time, everywhere, the authors of the report wrote.

Go here to see the original:
ASCO Names Molecular Profiling in GI Cancers as Advance of the Year - OncLive

Circularity Healthcare Announces Expansion with Global CRO of Series of Successful Pivotal Human Clinical Trials to Study Use of D’OXYVA for Rapid,…

PASADENA, Calif., Feb. 1, 2021 /PRNewswire/ --Circularity Healthcare announced it had successfully executed a contract with the Professional Educational Research Institute (PERI) in 2020 to immediately begin a new clinical trial to study the use of D'OXYVA to help prevent amputations and treat human diabetic foot ulcers at one-tenth the time and cost, and at least five times the efficacy of competing modalities. A widely recognized global clinical research organization (CRO), PERI will specifically study at multiple sites at prestigious U.S. universities the use of D'OXYVA to help address the recent epidemic of DFUs occurring in diabetic patients due to long-term pandemic quarantines and stay-at-home orders. Manufactured by Circularity, D'OXYVA is a painless, noninvasive transdermal delivery system used in minutes to significantly improve blood perfusion, tissue oxygenation, and wound healing even where standard treatments have failed.

"D'OXYVA's pivotal human clinical trial for complete healing of diabetic foot ulcershas been approved by the Western Institutional Review Board (WIRB), the largest in the world, and will include over a dozen high profile research sites at top U.S. universities and clinics," said Senior Sales and Marketing Manager for Circularity, Jennifer Boadilla-Pelaez, RN. "Thousands of competing products in the past nearly twenty-five years have failed in achieving what D'OXYVAhas obtained in terms of regulatory approvals, clinical safety and efficacy in the past seven years. This is truly a game-changing milestone, not just for the company itself, but the entire medical community and the world and a preliminary report with meaningful results is expected within6 months from starting the pivotal trial," said Dr. Charles M. Zelen, PERI's CEO.

DFUs are a major wound complication arising out of diabetes mellitus and occur in 313% of global diabetes patients, affecting millions of people. DFUs are caused by a variety of factors including decreased activity, diminished blood circulation, and people with underlying health conditions like diabetes are at higher risk for complications from COVID-19. Healthcare workers can expect to see far more instances of this persistent problem, especially with quarantine lockdowns, and it represents a significant health and economic risk to both patients and the overall healthcare system. Effective treatments that can reduce DFU recovery time, like D'OXYVA, are absolutely crucial to combatting this newest wound epidemic.

About Circularity Healthcare LLC

Circularity Healthcare is an emerging world leader in proprietary circulatory health and noninvasive delivery technologies, committed to helping improve quality of life by developing, manufacturing, and marketing medical, pharmaceutical, and consumer health products. Circularity specializes in groundbreaking noninvasive technologies for affordable and portable transdermal delivery systems, and is currently pursuing regulatory approval worldwide as a way of treating cardiovascular and microcirculatory blood flow issues, as well as immune and autonomic nervous system disorders. Learn more at: http://www.CircularityHealthcare.com.

About Professional Education and Research Institute, Inc.

PERI was established in 2005 as a premier CRO to manage Phase I - IV clinical trials around the world. PERI conducts clinical trials in both pharmaceutical and orthopedic research and performs specialty research in diabetic wound care, venous leg disease, neuropathy, peripheral vascular disease and gene therapy. One of the most unique advantages of choosing PERI as a partner in clinical trial management is a feature few CRO's can match, which is our contracted sites throughout the United States, including IBC-certified sites. Learn more at: http://www.periedu.com

Media Contact: Jennifer Boadilla-Pelaez 626-240-0956 [emailprotected]

SOURCE Circularity Healthcare LLC

http://www.CircularityHealthcare.com

See original here:
Circularity Healthcare Announces Expansion with Global CRO of Series of Successful Pivotal Human Clinical Trials to Study Use of D'OXYVA for Rapid,...